Zimmer Biomet Holdings, Inc. (ZBH) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 a...
Zimmer Biomet Holdings, Inc. (ZBH) currently trades at a P/E ratio of 25.60 (historical range: 19.93–103.57, median: 23.57), placing it at the 80th percentile — expensive relative to its history, P/S ratio of 2.32 (range: 1.85–3.45, 34th percentile — below its historical average), EV/EBITDA of 67.94 (range: 19.44–95.09, 86th percentile).
Over the historical period (2024-08-30 to 2026-08-28), Zimmer Biomet Holdings, Inc.'s P/E ratio has contracted by 51% over the observed period (from an average of 47.3 to 23.3).
Zimmer Biomet Holdings, Inc. appears slightly overvalued relative to its historical range, with most valuation metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 25.60 | 19.93 | 23.57 | 103.57 | 80th | expensive relative to its history |
| P/S Ratio | 2.32 | 1.85 | 2.45 | 3.45 | 34th | below its historical average |
| EV/EBITDA | 67.94 | 19.44 | 40.76 | 95.09 | 86th | expensive relative to its history |
| FCF Yield | 0.02 | 0.01 | 0.04 | 0.09 | 4th | expensive relative to its history |